Crohn's Disease: The Pros and Cons of Current Treatment Options
Apply for CME Credit Online
Purpose
This program is intended to educate healthcare providers, through expert examination and discussion, about the effectiveness and limitations of several classes of medications and where they belong in the current treatment paradigm. Discussants are Dr. Russell Cohen, Dr. Marla Dubinsky, and Dr. Edward Loftus.
Program Overview
Although Crohn's disease is usually chronic, current medical therapies can help control the course of the disease, allowing many patients to experience long periods of symptom-free remission. However, there are still many shortcomings associated with the various classes of agents available to clinicians today, including suboptimal efficacy, lack of compliance and potential safety issues.
Audience
Clinical gastroenterologists in academia and community practice, gastroenterology trainees, nurse practitioners, physician assistants, as well as other GI healthcare providers.
Learning Objectives
This Conversations program, focused on the effective management of patients with Crohn’s disease, will enable participants to:
- List the available pharmacological options available for the treatment of Crohn's disease
- Understand the effectiveness and limitations of several classes of medications used to treat Crohn's disease
- Optimally utilize the available agents in their clinical practice
Accreditation Statement
The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians
Designation Statement
The AGA Institute designates this educational activity for a maximum of
0.5 AMA PRA Category 1 Credit(s) TM.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty
Russell Cohen, MD (Program Moderator)
Associate Professor of Medicine
University of Chicago School of Medicine
Marla Dubinsky, MD
Director, Pediatric Inflammatory Bowel Disease Center
Cedars-Sinai Medical Center
Edward V. Loftus, Jr, MD
Associate Professor of Medicine
Mayo Medical School
Faculty Disclosure Information
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners
Russell Cohen, MD
Grant/Research Support: Centecor
Speakers' Bureau: Abbott, Astra-Zeneca, Axcan-Scandipharm, Proctor and Gamble, Prometheus, Salix, Schering-Plough, Shire, Tanabe, UCB
Consultant: Abbott, Axcan-Scandipharm, Centecor, Elan, Isis, NPS, Protein-Design Labs, UCB
Additional Disclosure: Family member who works for Centecor and owns stock in Johnson and Johnson
Marla Dubinsky, MD
Grant/Research Support: Centecor, UCB
Consultant: Centecor, Prometheus, Proctor and Gamble, Salix
Honoraria: Centecor, Prometheus, Salix
Ad Boards: Elan, UCB, Salix, Shire
Edward V. Loftus, Jr, MD
Grant/Research Support: Abbott, Schering-Plough
Consultant: Abbott, UCB, Elan, Prometheus, Shire
Suggested Minimum Software Requirements
Windows Me / XP / 2000.
800 MHz P3 processor.
256 MB RAM.
Microsoft Internet Explorer (6.0 or higher).
16-bit sound card and Windows Media Player (9.0 or greater).
Video Card capable of 16-bit color.
Adobe Reader 6.0 or greater.
Release Date: May 2007
Expiration Date: May 2009
Fee
Free-of-charge
Sponsorship and Support
Sponsored by the AGA Institute. This program is supported through an educational
grant from Elan Pharmaceuticals, Inc., and Biogen Idec.